BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade
AUTHORS
Nikbakht, et al
Programs
OPN-51107
https://doi.org/10.1016/j.jid.2018.12.024
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
AUTHORS
Ozer , et al
Programs
OPN-51107
https://doi.org/10.1158/2159-8290.CD-17-0902
Resistance to BET inhibitors involves the Wnt/β-catenin Pathway in Uveal Melanoma
AUTHORS
Ambrosini, et al
Programs
OPN-51107
Download PDF
Response and Resistance to Bromodomain Inhibition in Acute Myeloid Leukemia
AUTHORS
Huang, et al
Programs
OPN-51107
Download PDF
Broad Anti-Tumor Activity of a Novel BET Bromodomain Inhibitor
AUTHORS
Ma, et al
Programs
OPN-51107
Download PDF
A novel inhibitor of BET family bromodomains demonstrates in vivo and in vitro potency in B-cell malignancy
AUTHORS
El-Gamal, et al
Programs
OPN-51107
Download PDF
Efficacy and Mechanismof Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies
AUTHORS
Mead, et al
Programs
OPN-51107
Download PDF